174 related articles for article (PubMed ID: 36425568)
1.
Yang G; Yang Y; Hu J; Xu H; Zhang S; Wang Y
Front Pharmacol; 2022; 13():984503. PubMed ID: 36425568
[No Abstract] [Full Text] [Related]
2. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
[TBL] [Abstract][Full Text] [Related]
3. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors.
Vasconcelos PENS; Gergis C; Viray H; Varkaris A; Fujii M; Rangachari D; VanderLaan PA; Kobayashi IS; Kobayashi SS; Costa DB
JTO Clin Res Rep; 2020 Sep; 1(3):. PubMed ID: 34104899
[TBL] [Abstract][Full Text] [Related]
4. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
Hamada A; Suda K; Nishino M; Obata K; Oiki H; Fukami T; Fukuda S; Fujino T; Ohara S; Koga T; Chiba M; Shimoji M; Ito M; Takemoto T; Soh J; Tsutani Y; Mitsudomi T
J Thorac Oncol; 2024 Jan; 19(1):71-79. PubMed ID: 37666482
[TBL] [Abstract][Full Text] [Related]
5. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
[TBL] [Abstract][Full Text] [Related]
6. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
Shaffer W; Kobayashi IS; Sentana-Lledo D; Sundararaman S; Lee MD; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
Lung Cancer; 2023 Jul; 181():107250. PubMed ID: 37196448
[TBL] [Abstract][Full Text] [Related]
7. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios.
Kobayashi IS; Viray H; Rangachari D; Kobayashi SS; Costa DB
Cells; 2021 Dec; 10(12):. PubMed ID: 34944068
[No Abstract] [Full Text] [Related]
8. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
[TBL] [Abstract][Full Text] [Related]
9. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
[TBL] [Abstract][Full Text] [Related]
10. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.
Qin Y; Jian H; Tong X; Wu X; Wang F; Shao YW; Zhao X
Mol Oncol; 2020 Aug; 14(8):1695-1704. PubMed ID: 32412152
[TBL] [Abstract][Full Text] [Related]
11. Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.
Kunimasa K; Nishino K; Kukita Y; Matsumoto S; Kawachi H; Kawamura T; Inoue T; Tamiya M; Honma K; Sugimoto N; Yamasaki T; Imamura F; Goto K; Kumagai T
Cancer Genet; 2021 Aug; 256-257():57-61. PubMed ID: 33901930
[TBL] [Abstract][Full Text] [Related]
12. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
Hu M; Zhong C; Wang J; Chen J; Zhou T
Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with
Xu CW; Wang WX; Wang D; Wang QM; Pu XX; Zhu YC; Huang JH; Yu ZY; Cui ZL; Chen XH; Li JL; Fang Y; Wang H; Zhuang W; Lan SJ; Cai X; Zhang YB; Gao WB; Wang LP; She KL; Rao CZ; Zhou YF; Fang MY; Miao LY; Lei L; Lv TF; Song Y
Transl Lung Cancer Res; 2020 Oct; 9(5):1853-1861. PubMed ID: 33209607
[TBL] [Abstract][Full Text] [Related]
14. Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations.
Wang Y; Li J; Zhou Y; Cao S; Ling X; Zhang Y; Nie W; Zhong H
Ann Transl Med; 2020 Oct; 8(20):1297. PubMed ID: 33209877
[TBL] [Abstract][Full Text] [Related]
15. The treatment of patients with non-small cell lung cancer carrying uncommon
Yang LL; Luo XZ; Xie LL; Lei XZ; Zhu J
Transl Cancer Res; 2023 Aug; 12(8):2197-2211. PubMed ID: 37701115
[TBL] [Abstract][Full Text] [Related]
16. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.
Lin YT; Liu YN; Wu SG; Yang JC; Shih JY
Clin Lung Cancer; 2017 May; 18(3):324-332.e1. PubMed ID: 28089594
[TBL] [Abstract][Full Text] [Related]
18. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies
in Non-small Cell Lung Cancer].
Wang Y; Chu T
Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):135-147. PubMed ID: 36872052
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
Hasegawa H; Yasuda H; Hamamoto J; Masuzawa K; Tani T; Nukaga S; Hirano T; Kobayashi K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
Lung Cancer; 2019 Jan; 127():146-152. PubMed ID: 30642543
[TBL] [Abstract][Full Text] [Related]
20. Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Huang WS; Li F; Gong Y; Zhang Y; Youngsaye W; Xu Y; Zhu X; Greenfield MT; Kohlmann A; Taslimi PM; Toms A; Zech SG; Zhou T; Das B; Jang HG; Tugnait M; Ye YE; Gonzalvez F; Baker TE; Nadworny S; Ning Y; Wardwell SD; Zhang S; Gould AE; Hu Y; Lane W; Skene RJ; Zou H; Clackson T; Narasimhan NI; Rivera VM; Dalgarno DC; Shakespeare WC
Bioorg Med Chem Lett; 2023 Jan; 80():129084. PubMed ID: 36423823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
